中国药物警戒
中國藥物警戒
중국약물경계
CHINESE JOURNAL OF PHARMACOVIGILANCE
2014年
11期
645-648
,共4页
徐卉%蒋军%夏宗玲%王明丽
徐卉%蔣軍%夏宗玲%王明麗
서훼%장군%하종령%왕명려
头孢匹胺%重症急性胰腺炎%血胰屏障%通透率
頭孢匹胺%重癥急性胰腺炎%血胰屏障%通透率
두포필알%중증급성이선염%혈이병장%통투솔
cefpiramide%sever acute pancreatitis%blood-pancreatic barrier%permeation ratio
目的：研究头孢匹胺（CPM）在重症急性胰腺炎（SAP）小鼠血胰屏障的通透性，为头孢匹胺防治胰腺组织感染提供理论依据。方法以20%L-精氨酸2 g·kg-1体重腹腔注射方法复制SAP模型。正常对照组和SAP模型组小鼠均尾静脉注射头孢匹胺42.5 mg·kg-1，在规定时间点取样，用高效液相色谱法（HPLC）测定血浆和胰腺组织中药物的浓度。结果头孢匹胺在正常动物组和SAP模型组血浆和胰腺中的处置均符合一室模型。正常动物组CPM对血胰屏障平均穿透率（PR）可达（49.2±38.4）%，血浆和胰腺组织中的t1/2分别为1.42 h和1.14 h，AUC分别为122.73 mg·h·L-1和69.88 mg·h·kg-1。SAP模型组PR平均可达（56.4±34.7）%，与正常动物组相比无显著性差异，胰腺组织中t1/2、C0及AUC0-∞与正常动物组相近。结论头孢匹胺在SAP小鼠胰腺中有良好的分布，值得向临床推荐用于预防和治疗胰腺感染。
目的：研究頭孢匹胺（CPM）在重癥急性胰腺炎（SAP）小鼠血胰屏障的通透性，為頭孢匹胺防治胰腺組織感染提供理論依據。方法以20%L-精氨痠2 g·kg-1體重腹腔註射方法複製SAP模型。正常對照組和SAP模型組小鼠均尾靜脈註射頭孢匹胺42.5 mg·kg-1，在規定時間點取樣，用高效液相色譜法（HPLC）測定血漿和胰腺組織中藥物的濃度。結果頭孢匹胺在正常動物組和SAP模型組血漿和胰腺中的處置均符閤一室模型。正常動物組CPM對血胰屏障平均穿透率（PR）可達（49.2±38.4）%，血漿和胰腺組織中的t1/2分彆為1.42 h和1.14 h，AUC分彆為122.73 mg·h·L-1和69.88 mg·h·kg-1。SAP模型組PR平均可達（56.4±34.7）%，與正常動物組相比無顯著性差異，胰腺組織中t1/2、C0及AUC0-∞與正常動物組相近。結論頭孢匹胺在SAP小鼠胰腺中有良好的分佈，值得嚮臨床推薦用于預防和治療胰腺感染。
목적：연구두포필알（CPM）재중증급성이선염（SAP）소서혈이병장적통투성，위두포필알방치이선조직감염제공이론의거。방법이20%L-정안산2 g·kg-1체중복강주사방법복제SAP모형。정상대조조화SAP모형조소서균미정맥주사두포필알42.5 mg·kg-1，재규정시간점취양，용고효액상색보법（HPLC）측정혈장화이선조직중약물적농도。결과두포필알재정상동물조화SAP모형조혈장화이선중적처치균부합일실모형。정상동물조CPM대혈이병장평균천투솔（PR）가체（49.2±38.4）%，혈장화이선조직중적t1/2분별위1.42 h화1.14 h，AUC분별위122.73 mg·h·L-1화69.88 mg·h·kg-1。SAP모형조PR평균가체（56.4±34.7）%，여정상동물조상비무현저성차이，이선조직중t1/2、C0급AUC0-∞여정상동물조상근。결론두포필알재SAP소서이선중유량호적분포，치득향림상추천용우예방화치료이선감염。
Objective To investigate the permeability of cefpiramide (CPM) through blood-pancreatic barrier in the mice with sever acute pancreatitis(SAP). Methods CPM (42.5 mg·kg-1 body weight) was intravenous injected to mice after abdominally injecting L-arginine to induce sever acute pancreatitis while normal saline injection as control. At the given time points, the serum and pancreatic samples were collected. The concentrations of CPM in the samples were measured by HPLC. Results The disposition of CPM in two groups fitted one compartment model. The average penetration ratios (PR) of the drug through the blood-pancreas barrier in normal control group was (49.2±38.4)%. The parameters in plasma were as follows:t1/2 1.42 h, C0 59.93 mg·L-1, AUC0-∞122.73 mg·h·L-1, and those in tissue were as follows: t1/2 1.14 h, C0 22.58 mg·kg-1, AUC0-∞69.88 mg·h·kg-1. In SAP group, there was no significant difference in average PR、t1/2、C0 and AUC0-∞of CPM in the tissue compared with the normal control group (P>0.05). Conclusion CPM was shown to have a fairly high distribution in the pancreas in the SAP mice. It is therefore proposed that CPM may be used clinically for the prevention and treatment of pancreatic infection.
